Division of Cardiothoracic Surgery, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Division of Heart Failure and Transplant Cardiology, Department of Cardiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Clin Transplant. 2020 Nov;34(11):e14060. doi: 10.1111/ctr.14060. Epub 2020 Aug 29.
Although temporary mechanical circulatory support (tMCS) for hemodynamic failure following heart transplantation is associated with increased early morbidity and mortality, the impact of etiology of graft dysfunction and long-term clinical implications are less well known. The objective of our study was to evaluate outcomes in patients who required venoarterial extracorporeal membrane oxygenation (VA ECMO) or temporary right ventricular assist device (RVAD) support for either primary or secondary early graft dysfunction. Hospital mortality in 27 patients who required tMCS following heart transplantation at our institution between 2007 and 2017 was 56%, 30% in patients with right ventricular dysfunction secondary to increased afterload, 60% in patients with primary graft dysfunction, and 100% in patients with graft failure secondary to coagulopathy with intraoperative bleeding or overwhelming sepsis. Conditional 1-year and 5-year survival was comparable between patients with, and without, the need for post-transplantation support with tMCS (98% and 89%; 92% and 65% at 1 and 5 years, P = .21). Etiology of early graft failure plays an important part in determining the short-term post-heart transplantation outcome. Although complications associated with tMCS use, such as renal dysfunction and infection, extend beyond index transplant hospitalization, long-term conditional survival is not compromised.
虽然心脏移植后因血液动力学衰竭而进行的临时机械循环支持(tMCS)与早期发病率和死亡率增加有关,但移植功能障碍的病因及其长期临床意义知之甚少。我们的研究目的是评估因原发性或继发性早期移植物功能障碍而需要静脉动脉体外膜肺氧合(VA ECMO)或临时右心室辅助装置(RVAD)支持的患者的结局。2007 年至 2017 年期间,我们机构的 27 例心脏移植后需要 tMCS 的患者的院内死亡率为 56%,其中因后负荷增加导致右心室功能障碍的患者为 30%,原发性移植物功能障碍的患者为 60%,因术中出血或败血症导致凝血功能障碍而导致移植物衰竭的患者为 100%。需要与不需要移植后 tMCS 支持的患者之间,1 年和 5 年的条件生存率无差异(98%和 89%;1 年和 5 年分别为 92%和 65%,P=0.21)。早期移植物衰竭的病因在确定心脏移植后的短期预后方面起着重要作用。尽管与 tMCS 使用相关的并发症,如肾功能障碍和感染,会延长至指数移植住院期间之外,但长期的条件生存率不受影响。